- Home
- ANIX vs PLYX Comparison
ANIX vs PLYX Comparison
Compare ANIX & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | PLYX |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 114.1M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | PLYX |
|---|---|---|
| Price | $2.82 | $5.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $9.00 | ★ $10.00 |
| AVG Volume (30 Days) | 82.4K | ★ 1.9M |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $2.20 |
| 52 Week High | $5.46 | $8.15 |
Technical Indicators
Market Signals| Indicator | ANIX | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 50.74 |
| Support Level | N/A | $2.44 |
| Resistance Level | $3.10 | $7.43 |
| Average True Range (ATR) | 0.17 | 1.10 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 10.00 | 54.49 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.